Clinical Trial

Long-term Study to Evaluate Safety and Persistence of GF-CART01

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-15; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Enrolling by Invitation 2026-06-10
Trial Details
NCT Number NCT06985576
Lead Sponsor GenomeFrontier Therapeutics TW Co., Ltd.
Conditions DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL), Primary Mediastinal Large B-Cell Lymphoma, High Grade B Cell Lymphoma
Enrollment 18 participants
Start Date 2026-02-26
Primary Completion 2041-05 (estimated)
Study Completion 2041-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-11